Fabrizio Cavalca

Monza, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution.

Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution.

Journal: NEJM evidence

Published: May 26, 2026

Association of hypomethylating agents + venetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phase.

Association of hypomethylating agents + venetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phase.

Journal: Leukemia research

Published: March 06, 2026

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

Journal: Blood advances

Published: February 27, 2026

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

Journal: Blood advances

Published: February 27, 2026

Neutrophil to lymphocyte ratio at diagnosis predicts venous thrombosis in prefibrotic primary myelofibrosis: results from a multicenter cooperative study.

Neutrophil to lymphocyte ratio at diagnosis predicts venous thrombosis in prefibrotic primary myelofibrosis: results from a multicenter cooperative study.

Journal: Annals of hematology

Published: July 23, 2025

An Uncommon Presentation of Sweet's Syndrome in Primary Myelofibrosis.

An Uncommon Presentation of Sweet's Syndrome in Primary Myelofibrosis.

Journal: Case reports in hematology

Published: June 05, 2025

Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea.

Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea.

Journal: Leukemia

Published: March 18, 2025

Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study.

Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study.

Journal: Leukemia research

Published: March 05, 2025

Next Generation Sequencing Identifies Subgroups of Patients With Triple Negative Primary Thrombocytosis With Different Clinical Thrombotic Outcomes.

Next Generation Sequencing Identifies Subgroups of Patients With Triple Negative Primary Thrombocytosis With Different Clinical Thrombotic Outcomes.

Journal: International journal of laboratory hematology

Published: September 30, 2024

Neutrophil-to-lymphocyte ratio (NLR) at diagnosis in essential thrombocythemia: A new promising predictor of thrombotic events.

Neutrophil-to-lymphocyte ratio (NLR) at diagnosis in essential thrombocythemia: A new promising predictor of thrombotic events.

Journal: Cancer

Published: June 28, 2024

Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype.

Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype.

Journal: Med (New York, N.Y.)

Published: December 02, 2023

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis.

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis.

Journal: Cancers

Published: September 11, 2023

Showing 1-12 of 26

Last Updated: 09/26/2026